Natriumvalproat G.L. (Sodium Valproate)

• Sodium valproate is an anticonvulsant indicated for several neurological and psychiatric conditions.
• Epilepsy: reduces the frequency and severity of generalized and focal seizures, improving overall seizure control.
• Bipolar disorder: provides mood stabilization, decreasing the risk of manic and depressive episodes in adult patients.
• Migraine prophylaxis: decreases the number of migraine attacks per month and may lessen associated headache intensity.

• Sodium valproate increases the concentration of gamma‑aminobutyric acid (GABA) in the brain by inhibiting its degradation, blocks voltage‑gated sodium channels, and modulates T‑type calcium channels. The enhanced GABAergic inhibition dampens hyper‑synchronous neuronal activity, while sodium‑channel blockade limits rapid depolarization, and calcium‑channel modulation curtails abnormal thalamic oscillations, collectively stabilizing neuronal firing.

Sodium valproate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Dizziness
• Tremor
• Weight gain
• Hair loss

Serious or Rare Side Effects

• Hepatic failure or severe liver injury
• Acute pancreatitis
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Thrombocytopenia or severe blood dyscrasias
• Hyperammonemic encephalopathy

• When prescribing sodium valproate, clinicians should consider several safety precautions.
• Pregnancy: Category D – use only if benefits outweigh fetal risk, as teratogenicity is documented.
• Liver function: Monitor hepatic enzymes before and during therapy, especially in patients with pre‑existing liver disease.
• Hematology: Regularly check platelet counts and complete blood count to detect thrombocytopenia or other blood abnormalities.
• Concomitant CNS depressants: Use caution as combined sedation may increase.
• Discontinuation: Do not stop abruptly; taper gradually to avoid seizure recurrence.
• Store at ambient temperature: Keep below 25 °C in the original container, protect from moisture and light.

Sodium valproate interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Carbamazepine, phenytoin, phenobarbital: strong enzyme inducers that markedly reduce valproate levels.
• Rifampin: induces metabolism, leading to loss of seizure control.
• Warfarin: valproate can potentiate anticoagulant effect, increasing INR.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: valproate may reduce hormonal efficacy, requiring additional contraceptive measures.
• Lamotrigine: concurrent use requires dose adjustment of lamotrigine to avoid skin reactions.
• Topiramate: combined use may increase risk of hyperammonemia.
• Aspirin or NSAIDs: may enhance bleeding risk when used with valproate.